

***Core indicators for monitoring the Ending the HIV Epidemic initiative  
(preliminary data): National HIV Surveillance System data reported  
through June 2021; and preexposure prophylaxis (PrEP) data reported  
through March 2021***

## **Advisory Statement**

Effective date: May 21, 2024

Publication date of referenced document: October 2021

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

**Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.**

# HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the Ending the  
HIV Epidemic Initiative (*Preliminary Data*):**  
**National HIV Surveillance System Data Reported  
through June 2021; and Preexposure Prophylaxis  
(PrEP) Data Reported through March 2021**



Centers for Disease  
Control and Prevention  
National Center for HIV/AIDS,  
Viral Hepatitis, STD, and  
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through June 2021 and preexposure prophylaxis (PrEP) data reported through March 2021.

*HIV Surveillance Data Tables* is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

### **Suggested citation**

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2021; and preexposure prophylaxis (PrEP) data reported through March 2021. *HIV Surveillance Data Tables* 2021;2(No. 4). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published October 2021. Accessed [date].

**On the Web:** <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

### **Confidential information, referrals, and educational material on HIV infection**

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

### **Acknowledgments**

*HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Jianmin Li, Xiaohong Hu, Baohua Wu, Kyung Lee, Weiming Zhu, Lei Yu, and Norma Harris.

Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for editing and desktop publishing this report.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

<b>Technical Notes</b>	4
<b>References</b>	6
<b>Tables</b>	
1a Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2020 through June 2021—United States (preliminary)	7
1b Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2020 through June 2021—United States and 6 dependent areas (preliminary)	8
1c Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2020 through June 2021—United States and 6 dependent areas (preliminary)	9
1d Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2020 through June 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by selected characteristics, January 2020–March 2021—44 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2020–March 2021—44 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2020–March 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged $\geq 16$ years, by selected characteristics—United States (preliminary)	18
3b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged $\geq 16$ years, by area of residence—United States and Puerto Rico (preliminary)	20
3c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged $\geq 16$ years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	23

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of June 2021 for the years 2020 and 2021, and data on preexposure prophylaxis (PrEP) coverage for the years 2019, 2020, and 2021 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

## TABULATION AND PRESENTATION OF DATA

### Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged  $\geq 13$  years with HIV diagnosed during January 2020 through June 2021 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2011–2015 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html> (*HIV Surveillance Report*, 2019).

### Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged  $\geq 13$  years whose infection was diagnosed during January 2020 through March 2021 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2020 through March 2021 and who had  $\geq 1$  CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2020 through March 2021. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2020 through March 2021 and was reported to NHSS through June 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/index.html> (*Monitoring selected national HIV prevention and care objectives*

by using HIV surveillance data—United States and 6 dependent areas, 2019).

### **Preexposure Prophylaxis (PrEP) Coverage**

PrEP coverage, reported as a percentage, is defined as the number of persons aged  $\geq 16$  years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged  $\geq 16$  years who had indications for PrEP during the specified year (Tables 3a–3c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

### **Persons prescribed PrEP**

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged  $\geq 16$  years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting with the 2019 data, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP. In addition, generic TDF/FTC for PrEP became available in the United States in October 2020. Starting with the 2020 data, generic TDF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity

data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

### **Geographic designations**

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

### **Persons with PrEP indications**

ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [8, 9]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [10].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019 through March 2021 by using the IQVIA data reported through March 2021. IQVIA conducts data quality



assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019, 2020, and 2021 PrEP coverage data; consequently, 2019 through March 2021 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 through March 2021 should be interpreted with caution and the awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

More information on calculating PrEP coverage can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/index.html> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019*).

## REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated June 2, 2021. Accessed September 23, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:<http://dx.doi.org/10.15585/mmwr.mm6918e2>
3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
6. U.S. Census Bureau. American Community Survey 5-year data (2009–2019). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Published December 10, 2020. Accessed September 23, 2021.
7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. [https://www.huduser.gov/portal/datasets/usps\\_crosswalk.html](https://www.huduser.gov/portal/datasets/usps_crosswalk.html). Updated June 2021. Accessed September 23, 2021.
8. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14.
9. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107.
10. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

**Table 1a. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by selected characteristics, January 2020 through June 2021—United States (*preliminary*)**

	2020 No.	2021 (January–June) No.
<b>Gender</b>		
Male	23,384	10,716
Female	5,236	2,313
Transgender male-to-female <sup>a</sup>	589	221
Transgender female-to-male <sup>a</sup>	39	12
Additional gender identity <sup>b</sup>	13	13
<b>Age at diagnosis (yr)</b>		
13–24	5,867	2,522
25–34	10,867	4,830
35–44	5,684	2,802
45–54	3,805	1,680
$\geq 55$	3,038	1,441
<b>Race/ethnicity</b>		
American Indian/Alaska Native	184	82
Asian	603	266
Black/African American	12,557	5,720
Hispanic/Latino <sup>c</sup>	7,636	3,443
Native Hawaiian/other Pacific Islander	61	32
White	7,562	3,548
Multiracial	658	184
<b>Transmission category<sup>d</sup></b>		
Male-to-male sexual contact	19,954	9,168
Injection drug use		
Male	1,131	508
Female	812	342
Male-to-male sexual contact and injection drug use	1,014	451
Heterosexual contact <sup>e</sup>		
Male	1,858	805
Female	4,436	1,974
Other <sup>f</sup>		
Male	29	17
Female	28	11
<b>Region of residence<sup>g</sup></b>		
Northeast	4,187	1,682
Midwest	3,925	1,653
South	15,297	7,543
West	5,852	2,397
<b>Total</b>	<b>29,261</b>	<b>13,275</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

<sup>a</sup> “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

<sup>e</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

<sup>g</sup> Data are based on residence at time of diagnosis of HIV infection.



**Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through June 2021—United States and 6 dependent areas (preliminary)**

	2020 No.	2021 (January–June) No.
<b>Gender</b>		
Male	23,633	10,836
Female	5,276	2,338
Transgender male-to-female <sup>a</sup>	591	221
Transgender female-to-male <sup>a</sup>	39	12
Additional gender identity <sup>b</sup>	13	13
<b>Age at diagnosis (yr)</b>		
13–24	5,918	2,548
25–34	10,948	4,873
35–44	5,746	2,833
45–54	3,852	1,706
≥55	3,088	1,460
<b>Race/ethnicity</b>		
American Indian/Alaska Native	184	82
Asian	603	266
Black/African American	12,559	5,721
Hispanic/Latino <sup>c</sup>	7,925	3,583
Native Hawaiian/other Pacific Islander	61	32
White	7,562	3,552
Multiracial	658	184
<b>Transmission category<sup>d</sup></b>		
Male-to-male sexual contact	20,139	9,266
Injection drug use		
Male	1,151	512
Female	814	343
Male-to-male sexual contact and injection drug use	1,019	451
Heterosexual contact <sup>e</sup>		
Male	1,899	822
Female	4,473	1,998
Other <sup>f</sup>		
Male	29	17
Female	28	11
<b>Region of residence<sup>g</sup></b>		
Northeast	4,187	1,682
Midwest	3,925	1,653
South	15,297	7,543
West	5,852	2,397
U.S. dependent areas	291	145
<b>Total</b>	<b>29,552</b>	<b>13,420</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

**Note.** Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

<sup>a</sup> “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

<sup>e</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

<sup>g</sup> Data are based on residence at time of diagnosis of HIV infection.

**Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through June 2021—United States and 6 dependent areas (*preliminary*)**

Area of residence	2020 No.	2021 (January–June) No.
Alabama	574	137
Alaska	29	8
Arizona	675	284
Arkansas	246	185
California	3,535	1,315
Colorado	309	146
Connecticut	170	82
Delaware	96	33
District of Columbia	200	51
Florida	3,456	2,233
Georgia	1,802	761
Hawaii	50	15
Idaho	32	22
Illinois	905	276
Indiana	438	201
Iowa	99	54
Kansas	138	68
Kentucky	294	163
Louisiana	730	465
Maine	16	15
Maryland	719	302
Massachusetts	429	73
Michigan	523	280
Minnesota	226	135
Mississippi	395	166
Missouri	363	236
Montana	14	6
Nebraska	72	34
Nevada	382	212
New Hampshire	30	14
New Jersey	761	381
New Mexico	78	42
New York	1,945	736
North Carolina	1,082	621
North Dakota	30	4
Ohio	887	254
Oklahoma	233	98
Oregon	183	90
Pennsylvania	775	374
Rhode Island	53	6
South Carolina	686	332
South Dakota	34	10
Tennessee	644	349
Texas	3,390	1,219
Utah	129	64
Vermont	8	1
Virginia	625	385
Washington	422	191
West Virginia	125	43
Wisconsin	210	101
Wyoming	14	2
<b>Subtotal</b>	<b>29,261</b>	<b>13,275</b>
<b>U.S. dependent areas</b>		
American Samoa	0	0
Guam	0	1
Northern Mariana Islands	0	0
Puerto Rico	289	143
Republic of Palau	0	0
U.S. Virgin Islands	2	1
<b>Subtotal</b>	<b>291</b>	<b>145</b>
<b>Total</b>	<b>29,552</b>	<b>13,420</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, January 2020 through June 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary)**

Area of residence	2020 No.	2021 (January–June) No.
<b>Arizona</b>		
Maricopa County	482	204
<b>California</b>		
Alameda County	152	72
Los Angeles County	1,237	429
Orange County	262	116
Riverside County	234	91
Sacramento County	64	27
San Bernardino County	243	74
San Diego County	280	92
San Francisco County	151	78
<b>District of Columbia</b>	200	51
<b>Florida</b>		
Broward County	478	308
Duval County	231	144
Hillsborough County	249	163
Miami-Dade County	814	572
Orange County	379	231
Palm Beach County	218	132
Pinellas County	155	83
<b>Georgia</b>		
Cobb County	122	43
DeKalb County	240	114
Fulton County	492	223
Gwinnett County	123	41
<b>Illinois</b>		
Cook County	687	198
<b>Indiana</b>		
Marion County	169	91
<b>Louisiana</b>		
East Baton Rouge Parish	124	80
Orleans Parish	106	70
<b>Maryland</b>		
Baltimore City	175	56
Montgomery County	84	42
Prince George's County	216	95
<b>Massachusetts</b>		
Suffolk County	130	28
<b>Michigan</b>		
Wayne County	228	115
<b>Nevada</b>		
Clark County	332	190
<b>New Jersey</b>		
Essex County	189	100
Hudson County	117	53

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, January 2020 through June 2021—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	2020 No.	2021 (January–June) No.
<b>New York</b>		
Bronx County	330	148
Kings County	443	147
New York County	296	103
Queens County	315	99
<b>North Carolina</b>		
Mecklenburg County	209	134
<b>Ohio</b>		
Cuyahoga County	190	80
Franklin County	203	63
Hamilton County	130	6
<b>Pennsylvania</b>		
Philadelphia County	330	107
<b>Puerto Rico</b>		
San Juan Municipio	71	33
<b>Tennessee</b>		
Shelby County	228	122
<b>Texas</b>		
Bexar County	278	98
Dallas County	641	241
Harris County	895	385
Tarrant County	283	52
Travis County	166	71
<b>Washington</b>		
King County	200	88

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–March 2021—44 states and the District of Columbia (preliminary)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2020				
<b>Gender</b>					
Male	21,803	18,000	82.6	3,803	17.4
Female	4,851	3,990	82.3	861	17.7
Transgender male-to-female <sup>a</sup>	552	451	81.7	101	18.3
Transgender female-to-male <sup>a</sup>	36	32	88.9	4	11.1
Additional gender identity <sup>b</sup>	11	10	90.9	1	9.1
<b>Age at diagnosis (yr)</b>					
13–24	5,494	4,413	80.3	1,081	19.7
25–34	10,147	8,341	82.2	1,806	17.8
35–44	5,291	4,367	82.5	924	17.5
45–54	3,509	2,980	84.9	529	15.1
≥55	2,812	2,382	84.7	430	15.3
<b>Race/ethnicity</b>					
American Indian/Alaska Native	179	145	81.0	34	19.0
Asian	576	503	87.3	73	12.7
Black/African American	11,769	9,419	80.0	2,350	20.0
Hispanic/Latino <sup>c</sup>	7,140	6,061	84.9	1,079	15.1
Native Hawaiian/other Pacific Islander	60	53	88.3	7	11.7
White	6,930	5,798	83.7	1,132	16.3
Multiracial	599	504	84.1	95	15.9
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact	18,739	15,544	83.0	3,194	17.0
Injection drug use					
Male	992	781	78.7	211	21.3
Female	750	591	78.9	158	21.1
Male-to-male sexual contact and injection drug use	929	745	80.2	184	19.8
Heterosexual contact <sup>e</sup>					
Male	1,680	1,368	81.4	312	18.6
Female	4,111	3,408	82.9	704	17.1
<b>Total<sup>f</sup></b>	<b>27,253</b>	<b>22,483</b>	<b>82.5</b>	<b>4,770</b>	<b>17.5</b>

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2020–March 2021—44 states and the District of Columbia (preliminary) (cont)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2021 (January–March)					
<b>Gender</b>					
Male	5,858	4,912	83.9	946	16.1
Female	1,254	1,042	83.1	212	16.9
Transgender male-to-female <sup>a</sup>	119	106	89.1	13	10.9
Transgender female-to-male <sup>a</sup>	9	9	100	0	0.0
Additional gender identity <sup>b</sup>	7	7	100	0	0.0
<b>Age at diagnosis (yr)</b>					
13–24	1,447	1,171	80.9	276	19.1
25–34	2,652	2,207	83.2	445	16.8
35–44	1,496	1,275	85.2	221	14.8
45–54	900	769	85.4	131	14.6
≥55	752	654	87.0	98	13.0
<b>Race/ethnicity</b>					
American Indian/Alaska Native	40	32	80.0	8	20.0
Asian	150	134	89.3	16	10.7
Black/African American	3,170	2,594	81.8	576	18.2
Hispanic/Latino <sup>c</sup>	1,881	1,624	86.3	257	13.7
Native Hawaiian/other Pacific Islander	19	16	84.2	3	15.8
White	1,884	1,586	84.2	298	15.8
Multiracial	103	90	87.4	13	12.6
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact	5,052	4,267	84.5	784	15.5
Injection drug use					
Male	244	185	75.6	60	24.4
Female	182	148	81.4	34	18.6
Male-to-male sexual contact and injection drug use	240	189	78.8	51	21.2
Heterosexual contact <sup>e</sup>					
Male	437	375	85.7	62	14.3
Female	1,075	897	83.5	178	16.5
<b>Total<sup>f</sup></b>	<b>7,247</b>	<b>6,076</b>	<b>83.8</b>	<b>1,171</b>	<b>16.2</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

**Note.** Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through March 2021 and reported to NHSS through June 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

<sup>a</sup> “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

<sup>e</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–March 2021—44 states and the District of Columbia (*preliminary*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2020</b>				
Alabama	574	461	80.3	113	19.7
Alaska	29	28	96.6	1	3.4
Arizona	675	568	84.1	107	15.9
Arkansas	246	201	81.7	45	18.3
California	3,535	2,962	83.8	573	16.2
Colorado	309	270	87.4	39	12.6
Connecticut	170	143	84.1	27	15.9
Delaware	96	77	80.2	19	19.8
District of Columbia	200	175	87.5	25	12.5
Florida	3,456	2,906	84.1	550	15.9
Georgia	1,802	1,513	84.0	289	16.0
Hawaii	50	43	86.0	7	14.0
Illinois	905	766	84.6	139	15.4
Indiana	438	323	73.7	115	26.3
Iowa	99	89	89.9	10	10.1
Louisiana	730	556	76.2	174	23.8
Maine	16	15	93.8	1	6.3
Maryland	719	632	87.9	87	12.1
Massachusetts	429	373	86.9	56	13.1
Michigan	523	442	84.5	81	15.5
Minnesota	226	199	88.1	27	11.9
Mississippi	395	286	72.4	109	27.6
Missouri	363	289	79.6	74	20.4
Montana	14	12	85.7	2	14.3
Nebraska	72	64	88.9	8	11.1
Nevada	382	323	84.6	59	15.4
New Hampshire	30	24	80.0	6	20.0
New Mexico	78	65	83.3	13	16.7
New York	1,945	1,676	86.2	269	13.8
North Carolina	1,082	888	82.1	194	17.9
North Dakota	30	25	83.3	5	16.7
Ohio	887	764	86.1	123	13.9
Oklahoma	233	180	77.3	53	22.7
Oregon	183	152	83.1	31	16.9
Rhode Island	53	48	90.6	5	9.4
South Carolina	686	606	88.3	80	11.7
South Dakota	34	30	88.2	4	11.8
Tennessee	644	476	73.9	168	26.1
Texas	3,390	2,550	75.2	840	24.8
Utah	129	109	84.5	20	15.5
Virginia	625	509	81.4	116	18.6
Washington	422	375	88.9	47	11.1
West Virginia	125	92	73.6	33	26.4
Wisconsin	210	185	88.1	25	11.9
Wyoming	14	13	92.9	1	7.1
<b>Total</b>	<b>27,253</b>	<b>22,483</b>	<b>82.5</b>	<b>4,770</b>	<b>17.5</b>



**Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–March 2021—44 states and the District of Columbia (*preliminary*) (*cont*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2021 (January–March)</b>				
Alabama	99	73	73.7	26	26.3
Alaska	4	4	100	0	0.0
Arizona	202	169	83.7	33	16.3
Arkansas	89	71	79.8	18	20.2
California	838	712	85.0	126	15.0
Colorado	88	80	90.9	8	9.1
Connecticut	57	51	89.5	6	10.5
Delaware	21	18	85.7	3	14.3
District of Columbia	38	35	92.1	3	7.9
Florida	1,177	1,009	85.7	168	14.3
Georgia	468	418	89.3	50	10.7
Hawaii	10	6	60.0	4	40.0
Illinois	215	188	87.4	27	12.6
Indiana	120	101	84.2	19	15.8
Iowa	29	26	89.7	3	10.3
Louisiana	233	190	81.5	43	18.5
Maine	8	8	100	0	0.0
Maryland	200	180	90.0	20	10.0
Massachusetts	50	48	96.0	2	4.0
Michigan	140	120	85.7	20	14.3
Minnesota	68	60	88.2	8	11.8
Mississippi	92	66	71.7	26	28.3
Missouri	137	108	78.8	29	21.2
Montana	4	4	100	0	0.0
Nebraska	17	15	88.2	2	11.8
Nevada	111	97	87.4	14	12.6
New Hampshire	6	6	100	0	0.0
New Mexico	21	20	95.2	1	4.8
New York	488	423	86.7	65	13.3
North Carolina	336	280	83.3	56	16.7
North Dakota	4	4	100	0	0.0
Ohio	171	149	87.1	22	12.9
Oklahoma	48	34	70.8	14	29.2
Oregon	48	39	81.3	9	18.8
Rhode Island	4	2	50.0	2	50.0
South Carolina	206	192	93.2	14	6.8
South Dakota	8	8	100	0	0.0
Tennessee	180	109	60.6	71	39.4
Texas	785	581	74.0	204	26.0
Utah	26	24	92.3	2	7.7
Virginia	212	180	84.9	32	15.1
Washington	109	98	89.9	11	10.1
West Virginia	19	16	84.2	3	15.8
Wisconsin	60	53	88.3	7	11.7
Wyoming	1	1	100	0	0.0
<b>Total</b>	<b>7,247</b>	<b>6,076</b>	<b>83.8</b>	<b>1,171</b>	<b>16.2</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through March 2021 and reported to NHSS through June 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–March 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	2020					2021 (January–March)				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
<b>Arizona</b>										
Maricopa County	482	411	85.3	71	14.7	140	117	83.6	23	16.4
<b>California</b>										
Alameda County	152	129	84.9	23	15.1	37	32	86.5	5	13.5
Los Angeles County	1,237	1,031	83.3	206	16.7	285	248	87.0	37	13.0
Orange County	262	235	89.7	27	10.3	62	53	85.5	9	14.5
Riverside County	234	191	81.6	43	18.4	63	47	74.6	16	25.4
Sacramento County	64	54	84.4	10	15.6	23	21	91.3	2	8.7
San Bernardino County	243	174	71.6	69	28.4	53	40	75.5	13	24.5
San Diego County	280	243	86.8	37	13.2	68	57	83.8	11	16.2
San Francisco County	151	143	94.7	8	5.3	43	42	97.7	1	2.3
<b>District of Columbia</b>	200	175	87.5	25	12.5	38	35	92.1	3	7.9
<b>Florida</b>										
Broward County	478	418	87.4	60	12.6	172	146	84.9	26	15.1
Duval County	231	186	80.5	45	19.5	81	66	81.5	15	18.5
Hillsborough County	249	211	84.7	38	15.3	71	63	88.7	8	11.3
Miami-Dade County	814	682	83.8	132	16.2	288	253	87.8	35	12.2
Orange County	379	324	85.5	55	14.5	127	109	85.8	18	14.2
Palm Beach County	218	174	79.8	44	20.2	73	58	79.5	15	20.5
Pinellas County	155	131	84.5	24	15.5	52	42	80.8	10	19.2
<b>Georgia</b>										
Cobb County	122	106	86.9	16	13.1	24	21	87.5	3	12.5
DeKalb County	240	204	85.0	36	15.0	78	72	92.3	6	7.7
Fulton County	492	423	86.0	69	14.0	126	112	88.9	14	11.1
Gwinnett County	123	97	78.9	26	21.1	27	25	92.6	2	7.4
<b>Illinois</b>										
Cook County	687	585	85.2	102	14.8	153	136	88.9	17	11.1
<b>Indiana</b>										
Marion County	169	128	75.7	41	24.3	59	49	83.1	10	16.9
<b>Louisiana</b>										
East Baton Rouge Parish	124	101	81.5	23	18.5	32	28	87.5	4	12.5
Orleans Parish	106	85	80.2	21	19.8	40	37	92.5	3	7.5
<b>Maryland</b>										
Baltimore City	175	152	86.9	23	13.1	43	37	86.0	6	14.0
Montgomery County	84	75	89.3	9	10.7	27	27	100	0	0.0
Prince George's County	216	194	89.8	22	10.2	59	51	86.4	8	13.6
<b>Massachusetts</b>										
Suffolk County	130	116	89.2	14	10.8	19	19	100	0	0.0

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2020–March 2021—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	2020					2021 (January–March)				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
<b>Michigan</b>										
Wayne County	228	188	82.5	40	17.5	68	59	86.8	9	13.2
<b>Nevada</b>										
Clark County	332	281	84.6	51	15.4	100	87	87.0	13	13.0
<b>New York</b>										
Bronx County	330	285	86.4	45	13.6	92	82	89.1	10	10.9
Kings County	443	376	84.9	67	15.1	106	88	83.0	18	17.0
New York County	296	254	85.8	42	14.2	73	63	86.3	10	13.7
Queens County	315	279	88.6	36	11.4	63	58	92.1	5	7.9
<b>North Carolina</b>										
Mecklenburg County	209	173	82.8	36	17.2	78	70	89.7	8	10.3
<b>Ohio</b>										
Cuyahoga County	190	170	89.5	20	10.5	51	48	94.1	3	5.9
Franklin County	203	179	88.2	24	11.8	39	33	84.6	6	15.4
Hamilton County	130	115	88.5	15	11.5	6	6	100	0	0.0
<b>Pennsylvania</b>										
Philadelphia County	330	285	86.4	45	13.6	67	54	80.6	13	19.4
<b>Tennessee</b>										
Shelby County	228	153	67.1	75	32.9	58	27	46.6	31	53.4
<b>Texas</b>										
Bexar County	278	187	67.3	91	32.7	66	45	68.2	21	31.8
Dallas County	641	482	75.2	159	24.8	157	118	75.2	39	24.8
Harris County	895	675	75.4	220	24.6	224	168	75.0	56	25.0
Tarrant County	283	206	72.8	77	27.2	41	26	63.4	15	36.6
Travis County	166	123	74.1	43	25.9	41	21	51.2	20	48.8
<b>Washington</b>										
King County	200	181	90.5	19	9.5	43	41	95.3	2	4.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2020 through March 2021 and reported to NHSS through June 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by selected characteristics—United States (*preliminary*)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
<b>Sex at birth</b>			
Male	252,373	989,200	25.5
Female	21,008	227,010	9.3
<b>Age (yr)</b>			
16–24	36,873	246,290	15.0
25–34	112,071	434,680	25.8
35–44	63,344	238,470	26.6
45–54	36,951	173,420	21.3
≥55	24,201	123,350	19.6
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	36,890	468,540	7.9
Hispanic/Latino <sup>e</sup>	42,985	312,820	13.7
Other	11,550	131,180	8.8
White	182,101	300,650	60.6
<b>Total</b>	<b>273,526</b>	<b>1,216,210</b>	<b>22.5</b>
	<b>2020</b>		
<b>Sex at birth</b>			
Male	277,207	989,200	28.0
Female	23,696	227,010	10.4
<b>Age (yr)</b>			
16–24	38,454	246,290	15.6
25–34	119,246	434,680	27.4
35–44	72,146	238,470	30.3
45–54	40,694	173,420	23.5
≥55	30,394	123,350	24.6
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	42,372	468,540	9.0
Hispanic/Latino <sup>e</sup>	48,838	312,820	15.6
Other	12,326	131,180	9.4
White	197,497	300,650	65.7
<b>Total</b>	<b>301,033</b>	<b>1,216,210</b>	<b>24.8</b>

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by selected characteristics—United States (*preliminary*) (*cont*)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021 (January–March)</b>		
<b>Sex at birth</b>			
Male	182,316	989,200	18.4
Female	11,472	227,010	5.1
<b>Age (yr)</b>			
16–24	17,894	246,290	7.3
25–34	74,221	434,680	17.1
35–44	51,250	238,470	21.5
45–54	27,985	173,420	16.1
≥55	22,606	123,350	18.3
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	26,205	468,540	5.6
Hispanic/Latino <sup>e</sup>	31,090	312,820	9.9
Other	7,677	131,180	5.9
White	129,048	300,650	42.9
<b>Total</b>	<b>194,020</b>	<b>1,216,210</b>	<b>16.0</b>

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated using data from IQVIA pharmacy database reported through March 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–March 2021 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

<sup>e</sup> Hispanic/Latino persons can be of any race.

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
Alabama	1,837	11,020	16.7
Alaska	232	1,780	13.0
Arizona	4,544	25,780	17.6
Arkansas	740	5,130	14.4
California	41,508	165,030	25.2
Colorado	4,332	25,120	17.2
Connecticut	2,660	9,560	27.8
Delaware	471	4,400	10.7
District of Columbia	5,805	12,950	44.8
Florida	21,693	125,330	17.3
Georgia	8,576	39,030	22.0
Hawaii	815	4,360	18.7
Idaho	471	4,790	9.8
Illinois	16,587	55,860	29.7
Indiana	2,960	22,170	13.4
Iowa	1,418	4,760	29.8
Kansas	903	5,060	17.8
Kentucky	1,609	12,990	12.4
Louisiana	3,926	15,920	24.7
Maine	636	3,950	16.1
Maryland	4,940	27,300	18.1
Massachusetts	9,283	24,900	37.3
Michigan	4,362	29,570	14.8
Minnesota	4,181	21,720	19.2
Mississippi	935	4,530	20.6
Missouri	3,481	18,370	18.9
Montana	267	2,290	11.7
Nebraska	615	2,180	28.2
Nevada	2,157	11,390	18.9
New Hampshire	616	3,020	20.4
New Jersey	5,666	25,280	22.4
New Mexico	1,074	6,800	15.8
New York	34,993	72,640	48.2
North Carolina	5,371	32,490	16.5
North Dakota	194	1,520	12.8
Ohio	6,113	40,320	15.2
Oklahoma	1,143	11,030	10.4
Oregon	3,358	19,750	17.0
Pennsylvania	10,113	36,490	27.7
Puerto Rico	330	9,700	3.4
Rhode Island	1,078	3,880	27.8
South Carolina	1,724	10,390	16.6
South Dakota	147	910	16.2
Tennessee	3,888	22,460	17.3
Texas	22,966	123,790	18.6
Utah	2,021	6,840	29.5
Vermont	337	1,060	31.8
Virginia	4,422	31,430	14.1
Washington	9,802	40,050	24.5
West Virginia	570	5,250	10.9
Wisconsin	2,461	12,980	19.0
Wyoming	93	890	10.4

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020</b>		
Alabama	1,927	11,020	17.5
Alaska	246	1,780	13.8
Arizona	5,047	25,780	19.6
Arkansas	876	5,130	17.1
California	42,399	165,030	25.7
Colorado	4,745	25,120	18.9
Connecticut	2,478	9,560	25.9
Delaware	463	4,400	10.5
District of Columbia	5,953	12,950	46.0
Florida	34,604	125,330	27.6
Georgia	9,746	39,030	25.0
Hawaii	904	4,360	20.7
Idaho	656	4,790	13.7
Illinois	15,951	55,860	28.6
Indiana	3,200	22,170	14.4
Iowa	1,513	4,760	31.8
Kansas	949	5,060	18.8
Kentucky	1,668	12,990	12.8
Louisiana	3,610	15,920	22.7
Maine	658	3,950	16.7
Maryland	4,809	27,300	17.6
Massachusetts	9,391	24,900	37.7
Michigan	4,697	29,570	15.9
Minnesota	4,197	21,720	19.3
Mississippi	1,095	4,530	24.2
Missouri	3,594	18,370	19.6
Montana	297	2,290	13.0
Nebraska	728	2,180	33.4
Nevada	2,495	11,390	21.9
New Hampshire	646	3,020	21.4
New Jersey	5,936	25,280	23.5
New Mexico	1,241	6,800	18.3
New York	34,080	72,640	46.9
North Carolina	6,166	32,490	19.0
North Dakota	218	1,520	14.3
Ohio	6,846	40,320	17.0
Oklahoma	1,525	11,030	13.8
Oregon	3,813	19,750	19.3
Pennsylvania	10,627	36,490	29.1
Puerto Rico	368	9,700	3.8
Rhode Island	1,148	3,880	29.6
South Carolina	2,124	10,390	20.4
South Dakota	146	910	16.0
Tennessee	5,171	22,460	23.0
Texas	27,527	123,790	22.2
Utah	2,380	6,840	34.8
Vermont	320	1,060	30.2
Virginia	5,164	31,430	16.4
Washington	10,005	40,050	25.0
West Virginia	526	5,250	10.0
Wisconsin	2,521	12,980	19.4
Wyoming	97	890	10.9



**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	2021 (January–March)		
Alabama	1,430	11,020	13.0
Alaska	153	1,780	8.6
Arizona	3,512	25,780	13.6
Arkansas	636	5,130	12.4
California	26,444	165,030	16.0
Colorado	3,060	25,120	12.2
Connecticut	1,574	9,560	16.5
Delaware	327	4,400	7.4
District of Columbia	3,998	12,950	30.9
Florida	20,483	125,330	16.3
Georgia	6,903	39,030	17.7
Hawaii	606	4,360	13.9
Idaho	435	4,790	9.1
Illinois	10,609	55,860	19.0
Indiana	2,260	22,170	10.2
Iowa	961	4,760	20.2
Kansas	645	5,060	12.7
Kentucky	1,108	12,990	8.5
Louisiana	2,408	15,920	15.1
Maine	462	3,950	11.7
Maryland	3,154	27,300	11.6
Massachusetts	5,304	24,900	21.3
Michigan	3,157	29,570	10.7
Minnesota	2,797	21,720	12.9
Mississippi	820	4,530	18.1
Missouri	2,322	18,370	12.6
Montana	182	2,290	7.9
Nebraska	521	2,180	23.9
Nevada	1,554	11,390	13.6
New Hampshire	424	3,020	14.0
New Jersey	3,874	25,280	15.3
New Mexico	832	6,800	12.2
New York	21,250	72,640	29.3
North Carolina	4,309	32,490	13.3
North Dakota	133	1,520	8.8
Ohio	4,666	40,320	11.6
Oklahoma	1,071	11,030	9.7
Oregon	2,297	19,750	11.6
Pennsylvania	7,304	36,490	20.0
Puerto Rico	271	9,700	2.8
Rhode Island	811	3,880	20.9
South Carolina	1,493	10,390	14.4
South Dakota	105	910	11.5
Tennessee	3,800	22,460	16.9
Texas	19,355	123,790	15.6
Utah	1,769	6,840	25.9
Vermont	202	1,060	19.1
Virginia	3,275	31,430	10.4
Washington	6,153	40,050	15.4
West Virginia	381	5,250	7.3
Wisconsin	1,488	12,980	11.5
Wyoming	60	890	6.7

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated using data from IQVIA pharmacy database reported through March 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–March 2021 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
<b>Arizona</b>			
Maricopa County	3,522	22,720	15.5
<b>California</b>			
Alameda County	2,167	8,930	24.3
Los Angeles County	13,660	67,450	20.3
Orange County	2,033	10,510	19.3
Riverside County	1,761	11,080	15.9
Sacramento County	949	5,920	16.0
San Bernardino County	752	11,890	6.3
San Diego County	3,701	14,500	25.5
San Francisco County	8,809	10,840	81.3
<b>District of Columbia</b>	5,805	12,950	44.8
<b>Florida</b>			
Broward County	3,742	20,470	18.3
Duval County	503	8,970	5.6
Hillsborough County	1,379	12,910	10.7
Miami-Dade County	6,521	21,760	30.0
Orange County	2,764	15,310	18.1
Palm Beach County	876	9,170	9.6
Pinellas County	1,106	9,530	11.6
<b>Georgia</b>			
Cobb County	557	3,070	18.1
DeKalb County	1,549	6,290	24.6
Fulton County	3,265	13,120	24.9
Gwinnett County	680	3,240	21.0
<b>Illinois</b>			
Cook County	13,550	39,060	34.7
<b>Indiana</b>			
Marion County	1,121	9,150	12.3
<b>Louisiana</b>			
East Baton Rouge Parish	490	1,810	27.1
Orleans Parish	1,509	4,590	32.9
<b>Maryland</b>			
Baltimore City	898	6,330	14.2
Montgomery County	909	5,770	15.8
Prince George's County	800	4,040	19.8
<b>Massachusetts</b>			
Suffolk County	2,755	6,520	42.3
<b>Michigan</b>			
Wayne County	1,206	9,270	13.0
<b>Nevada</b>			
Clark County	1,848	11,670	15.8
<b>New Jersey</b>			
Essex County	679	4,090	16.6
Hudson County	1,035	4,650	22.3

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019 (cont)</b>		
<b>New York</b>			
Bronx County	2,221	5,570	39.9
Kings County	7,453	15,650	47.6
New York County	13,906	15,540	89.5
Queens County	3,865	9,230	41.9
<b>North Carolina</b>			
Mecklenburg County	1,338	8,450	15.8
<b>Ohio</b>			
Cuyahoga County	949	7,520	12.6
Franklin County	2,039	11,620	17.5
Hamilton County	553	7,720	7.2
<b>Pennsylvania</b>			
Philadelphia County	3,637	9,840	37.0
<b>Puerto Rico</b>			
San Juan Municipio	-- <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	641	6,450	9.9
<b>Texas</b>			
Bexar County	1,483	11,920	12.4
Dallas County	4,037	28,670	14.1
Harris County	4,884	40,670	12.0
Tarrant County	1,455	11,340	12.8
Travis County	4,545	11,590	39.2
<b>Washington</b>			
King County	6,856	17,890	38.3

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020</b>		
<b>Arizona</b>			
Maricopa County	3,889	22,720	17.1
<b>California</b>			
Alameda County	2,039	8,930	22.8
Los Angeles County	14,799	67,450	21.9
Orange County	2,224	10,510	21.2
Riverside County	1,913	11,080	17.3
Sacramento County	968	5,920	16.4
San Bernardino County	820	11,890	6.9
San Diego County	3,767	14,500	26.0
San Francisco County	8,099	10,840	74.7
<b>District of Columbia</b>	5,953	12,950	46.0
<b>Florida</b>			
Broward County	6,688	20,470	32.7
Duval County	745	8,970	8.3
Hillsborough County	1,519	12,910	11.8
Miami-Dade County	10,303	21,760	47.3
Orange County	3,876	15,310	25.3
Palm Beach County	3,023	9,170	33.0
Pinellas County	1,207	9,530	12.7
<b>Georgia</b>			
Cobb County	644	3,070	21.0
DeKalb County	1,707	6,290	27.1
Fulton County	3,558	13,120	27.1
Gwinnett County	791	3,240	24.4
<b>Illinois</b>			
Cook County	12,864	39,060	32.9
<b>Indiana</b>			
Marion County	1,198	9,150	13.1
<b>Louisiana</b>			
East Baton Rouge Parish	525	1,810	29.0
Orleans Parish	1,343	4,590	29.3
<b>Maryland</b>			
Baltimore City	857	6,330	13.5
Montgomery County	918	5,770	15.9
Prince George's County	814	4,040	20.1
<b>Massachusetts</b>			
Suffolk County	2,806	6,520	43.0
<b>Michigan</b>			
Wayne County	1,238	9,270	13.4
<b>Nevada</b>			
Clark County	2,099	11,670	18.0
<b>New Jersey</b>			
Essex County	709	4,090	17.3
Hudson County	1,042	4,650	22.4

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020 (cont)</b>		
<b>New York</b>			
Bronx County	2,051	5,570	36.8
Kings County	7,379	15,650	47.2
New York County	13,620	15,540	87.6
Queens County	3,826	9,230	41.5
<b>North Carolina</b>			
Mecklenburg County	1,567	8,450	18.5
<b>Ohio</b>			
Cuyahoga County	959	7,520	12.8
Franklin County	2,309	11,620	19.9
Hamilton County	626	7,720	8.1
<b>Pennsylvania</b>			
Philadelphia County	3,484	9,840	35.4
<b>Puerto Rico</b>			
San Juan Municipio	-- <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	818	6,450	12.7
<b>Texas</b>			
Bexar County	1,765	11,920	14.8
Dallas County	5,142	28,670	17.9
Harris County	5,960	40,670	14.7
Tarrant County	1,647	11,340	14.5
Travis County	5,070	11,590	43.7
<b>Washington</b>			
King County	6,955	17,890	38.9

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	2021 (January–March)		
<b>Arizona</b>			
Maricopa County	2,761	22,720	12.2
<b>California</b>			
Alameda County	1,103	8,930	12.4
Los Angeles County	9,771	67,450	14.5
Orange County	1,486	10,510	14.1
Riverside County	1,344	11,080	12.1
Sacramento County	544	5,920	9.2
San Bernardino County	540	11,890	4.5
San Diego County	2,378	14,500	16.4
San Francisco County	4,589	10,840	42.3
<b>District of Columbia</b>	3,998	12,950	30.9
<b>Florida</b>			
Broward County	4,206	20,470	20.5
Duval County	485	8,970	5.4
Hillsborough County	978	12,910	7.6
Miami-Dade County	5,912	21,760	27.2
Orange County	2,552	15,310	16.7
Palm Beach County	1,243	9,170	13.6
Pinellas County	850	9,530	8.9
<b>Georgia</b>			
Cobb County	440	3,070	14.3
DeKalb County	1,233	6,290	19.6
Fulton County	2,594	13,120	19.8
Gwinnett County	549	3,240	16.9
<b>Illinois</b>			
Cook County	8,595	39,060	22.0
<b>Indiana</b>			
Marion County	898	9,150	9.8
<b>Louisiana</b>			
East Baton Rouge Parish	345	1,810	19.1
Orleans Parish	903	4,590	19.7
<b>Maryland</b>			
Baltimore City	554	6,330	8.8
Montgomery County	583	5,770	10.1
Prince George's County	572	4,040	14.2
<b>Massachusetts</b>			
Suffolk County	1,484	6,520	22.8
<b>Michigan</b>			
Wayne County	821	9,270	8.9
<b>Nevada</b>			
Clark County	1,294	11,670	11.1
<b>New Jersey</b>			
Essex County	454	4,090	11.1
Hudson County	676	4,650	14.5

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through March 2021, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021 (January–March) (<i>cont</i>)</b>		
<b>New York</b>			
Bronx County	1,178	5,570	21.1
Kings County	4,615	15,650	29.5
New York County	8,932	15,540	57.5
Queens County	2,344	9,230	25.4
<b>North Carolina</b>			
Mecklenburg County	1,165	8,450	13.8
<b>Ohio</b>			
Cuyahoga County	664	7,520	8.8
Franklin County	1,653	11,620	14.2
Hamilton County	393	7,720	5.1
<b>Pennsylvania</b>			
Philadelphia County	2,206	9,840	22.4
<b>Puerto Rico</b>			
San Juan Municipio	-- <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	518	6,450	8.0
<b>Texas</b>			
Bexar County	1,273	11,920	10.7
Dallas County	3,752	28,670	13.1
Harris County	4,168	40,670	10.2
Tarrant County	1,184	11,340	10.4
Travis County	3,466	11,590	29.9
<b>Washington</b>			
King County	4,272	17,890	23.9

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

*Note.* Data for years 2020 and 2021 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated using data from IQVIA pharmacy database reported through March 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019, 2020, and January–March 2021 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Data value <40 was not reported due to unreliability.